Prime Medicine, Inc. (PRME)
Nasdaq · Common stock · Biological Products, (no Diagnostic Substances)
As of Oct 21, 4:00 PM ET15 min delayedAbout 15 minutes behind the market. Every member plan is real time.
Follow PRME in real time
Real-time quotes, Pro Charting, the scanner and the alert feed on PRME and every other US listing.
Start 5 days freeTry Premium Membership free for 5 days. Card required. After 5 days it is $149 per month or $1,099 per year until you cancel. First-time members only.
PRME at a glance
Key statistics
$711.00M
Market capitalization
- Previous close
- $3.92
- Open
- $3.92
- Day range
- $3.80 – $4.01
- Volume
- 2.44M
- Average volume (30 sessions)
- 4.44M
- Shares outstanding
- 181.38M
- Earnings per share
- $(1.04)
- Price / book
- 17.9
- Price / sales
- 174.6
- Beta (1 year, vs SPY)
- 2.31
Where the price sits in its year
52-week range
31% of the range
- Below the 52-week high
- -39.5%
- Above the 52-week low
- +42.7%
Completed sessions through Oct 21, 2026
Technical snapshot
Above its 50-day and 200-day averages
- 20-day average
- $3.39+12.3%
- 50-day average
- $3.37+12.9%
- 200-day average
- $3.48+9.4%
Between the conventional 30 and 70 bands.
+21.7%
1 week
+7.6%
1 month
+28.3%
3 months
+9.8%
Year to date
-38.3%
1 year
Price change over each window, from completed sessions. Past performance does not indicate future results.
Every plan: MACD, ATR, the 20- and 50-day ranges, five-year and all-history extremes and the full indicator set, live on Pro Charting.The member platform, in real time
What members do with PRME
PRME on Pro Charting
Every intraday interval in real time, the drawing kit and the full set of technical studies on PRME.
See the plans →
Every planScreen names like PRME
The real-time scanner: price, volume, technical, fundamental and chart-pattern filters across the whole US market.
See the plans →
Analysis Tools OnlySet a price line on PRME
Put PRME on your watchlist, draw the levels you care about, and My Dashboard tracks where it trades against them.
See the plans →
Stock Alerts + ToolsOpen alerts on PRME
See whether there is an open premium alert on PRME, with its entry, stop and exit, each one reviewed by an analyst before it is sent.
See the plans →
From the public news wire
PRME headlines
- Prime Medicine Announces First Patient Dosed in Global Phase 1/2 Clinical Trial of PM577a for H1069Q-Mutated Wilson Disease
GlobeNewswire Inc. · Oct 5, 2026
- Prime Medicine to Participate in Upcoming Investor Conferences
GlobeNewswire Inc. · Feb 25, 2026
- Prime Medicine Announces The New England Journal of Medicine Publication of PM359 Clinical Data for the Treatment of Chronic Granulomatous Disease
GlobeNewswire Inc. · Dec 7, 2025
- Prime Medicine Reports Third Quarter 2025 Financial Results and Provides Business Updates
GlobeNewswire Inc. · Nov 7, 2025
- Prime Medicine Announces Pricing of Public Offering
GlobeNewswire Inc. · Jul 30, 2025
- Prime Medicine Unveils Program for the Treatment of Alpha-1 Antitrypsin Deficiency (AATD)
GlobeNewswire Inc. · Mar 18, 2025
- Prime Medicine Reports Third Quarter 2024 Financial Results and Provides Business Updates
GlobeNewswire Inc. · Nov 12, 2024
- Prime Medicine Inks Cell Therapy Pact With Bristol Myers Squibb Worth Over $3.5B, Streamlines Pipeline
Benzinga · Sep 30, 2024
SEC Form 4, most recent first
Insider filings
Kelly Michael Aaron
+75.0K
Director · Grant or award
· Jun 5, 2026
Schenkein David P
+75.0K
Director · Grant or award
· Jun 5, 2026
Cahill Thomas
+75.0K
Director · Grant or award
· Jun 5, 2026
Chung Wendy
+75.0K
Director · Grant or award
· Jun 5, 2026
NELSEN ROBERT
+75.0K
Director, 10% owner · Grant or award
· Jun 5, 2026
Foster-Cheek Kaye I
+75.0K
Director · Grant or award
· Jun 5, 2026
Marrazzo Jeffrey D
+75.0K
Director · Grant or award
· Jun 5, 2026
Makhni Svetlana Ni
+800.0K
Chief Financial Officer · Grant or award
· Apr 16, 2026
About Prime Medicine, Inc.
Prime Medicine Inc is a biotechnology company focused on developing a new class of genetic medicines designed to provide durable, and potentially curative, treatment options for patients with diseases driven by defined genetic alterations, acquired cellular dysfunction, or dysregulated gene expression. Its program, PM577 for Wilson Disease, is designed to initially correct the H1069Q mutation in the ATP7B gene and is supported by preclinical data showing targeted correction and restoration of copper homeostasis in animal models. In addition, PM647 is being developed for alpha-1 antitrypsin deficiency, or AATD, another liver targeted disease with substantial unmet need.
- Exchange
- Nasdaq
- Security
- Common stock
- Industry
- Biological Products, (no Diagnostic Substances)
- Headquarters
- Cambridge, MA
- Employees
- 146
- Listed since
- Oct 20, 2022
- Website
- primemedicine.com
Pick the desk that fits how you trade
Analysis Tools Only for the real-time scanner, Pro Charting and the research desk. Stock Alerts + Tools for the human-reviewed alert feed. Premium Membership for both, at one price.
Try Premium Membership free for 5 days. Card required. After 5 days it is $149 per month or $1,099 per year until you cancel. First-time members only.
Other plans from $39 a month. Pay by card, Apple Pay, Google Pay, Link, Cash App Pay or Amazon Pay through Stripe.